Target
$283.92 → $283.78
Current stock research snapshot · 8/22/26 Fresh
LHLabcorp Holdings
Investment conviction●●○○○2 of 5 · current snapshot
Research target$283.78Current stock price target
Investment thesis statusSTRENGTHENEDLast reviewed 8/22/26
Market cap$23.53BSnapshot value · 8/22/26
Research history
See all LH changes ↗What changed
Thesis status
INTACT → STRENGTHENED
Last reviewed
7/8/26 → 8/22/26
Target
$283.94 → $283.92
Diagnostics network + specialty testing. Labcorp is the largest clinical lab network in the US. Drug development services (CRO-adjacent) add diversification.
Specialty testing growth (oncology, neurology); drug development services (Fortrea spin-off complete — now pure-play lab + CRO-adjacent); consumer testing.
Same as DGX: reimbursement pressure, labor inflation, PAMA risk. Fortrea spin-off removed the pure CRO exposure.
Bullish — New all-time high Aug 24; FDA-cleared Alzheimer's blood test announcement. [X search Aug 2026]
Snapshot · 8/22/26🟢 Lean-Bull · ins-$4.0M · 13F 15+/10-×0.5 · short↓0.27
Snapshot · 8/22/26Timestamped research update
Deep research update
310 words · Updated Aug 22, 2026
Research in development: this latest 310-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Labcorp Holdings (NYSE: LH) operates the largest U.S. independent clinical-laboratory network — routine + esoteric/specialty testing (Diagnostics Laboratories, ~78% of revenue) and a biopharma central-lab / CRO business (Biopharma Laboratory Services, ~22%, legacy Covance). It is the physical "measure" layer of healthspan: 2,200+ PSCs, 7,000+ in-office phlebotomists, ~175M patient encounters/yr.
FY2025 revenue $13,951.7M; Q2 2026 revenue $3,731.1M (+5.8% YoY), OI margin 12.1% (+90bps), adjusted EPS $4.99 (+14.9%). FY2026 guidance raised to $14,710–14,827M (+5.4–6.3%) and adj EPS $18.10–18.55.
Diagnostics is the front door of the healthspan "Maintain" layer — you cannot manage (or extend) health you cannot measure. Labcorp owns the physical last-mile (collection network) + regulatory standing (CLIA/FDA) + the oncology/esoteric test portfolio that captures the shift from sick-care to preventive screening (ColoSense, MRD, CDx).
- 2,200+ PSCs + 7,000+ in-office phlebotomists ≈ 9,200 collection points (FY2025 10-K).
- Dx price/mix +3.5% (FY25) / +3.0% (Q2 26) — positive pricing in a deflationary sector.
- BLS backlog $8.73B, book-to-bill 1.03, NTM conversion $2.75B ≈ 84% of next-year BLS revenue contracted (EX-99.1).
- Central Labs +9.8% YoY vs Early Development −1.4% — the central-lab toll-road is the growth engine.
- DoD contract re-award for military-hospital lab testing; ColoSense (first FDA-approved RNA CRC screen) nationwide launch with Labcorp as primary distributor.
Physical collection network + CLIA/FDA regulatory standing + payer/Epic integration + central-lab contracted backlog. Irreplicable without ~$2.2B+ capex and multi-year credentialing.
- Quest duopoly caps pricing; 2027+ PAMA 15%/yr cuts structurally deflate the routine basket.
- China BGI/MGI genomics discounting commoditizes the esoteric/sequencing growth niche.
- Exact Medicare CLFS revenue mix (what % of Dx is Medicare) to size the 2027+ 15%/yr cap exposure — needs 10-K Medicare-revenue disclosure.
- ColoSense / Plasma Detect MRD reimbursement traction (covered lives) — next earnings.
STRENGTHENED.